Dotremin Folic Acid, Vitamin D3 1 mg; 250 ug Tablet, 30-count — NDC 59088-524-54 (Billing 59088-0524-54)
This is a package of 30 tablets of Dotremin Folic Acid, Vitamin D3 1 mg; 250 ug Tablet from PureTek Corporation, marketed since Jan 2022 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 59088-524-54 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 59088 labeler · 524 product · 54 package
- Package marketed since
- Jan 14, 2022
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 30 EA per package
- Barcode (UPC)
- 0359088524541
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 082759
- GCN: 51357
- GPI-14 (Medi-Span): 82991502400335
- HICL (First Databank): 041600
- AHFS class code: 88:08.00.00
- RxCUI (RxNorm): 2569082
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Vitamin D class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Dotremin is an oral tablet containing folic acid and vitamin D3. Folic acid is a B vitamin typically used to support cell division and DNA synthesis, and is commonly included in supplements to help maintain adequate folate levels. Vitamin D3 is typically used to support bone health and calcium absorption. This product is marketed without an approved FDA application.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 8, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 59088-0524-54 You're viewing this Main listing | 30 TABLET in 1 BOTTLE, PLASTIC | 2022-01-14 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Folditam 1 mg/1; 250 ug 59088-0185-54 | PureTek | 30 tablets | — | — | FDA listed | — |
| Dotremin 1 mg/1; 250 ugthis 59088-0524-54 | PureTek | 30 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from PureTek Corporation labeler code 59088
- Micotrin AP Miconazole Nitrate 2 g/85g Powder NDC 59088-478-07
- Circatrix Capsaicin .05 g/100g Cream NDC 59088-479-05
- Foliflex Ferrous Fumarate, Folic Acid 1500 ug; 250 mg; 13.75 ug; 45 mg; 3.25 mg; 3.35 mg; 22.5 mg; 6 mg; 500 ug Tablet NDC 59088-480-58
- Lidotran Lidocaine Hydrochloride 38.8 mg/g Cream NDC 59088-483-07
- Camphotrol camphor, menthol 4 g/100g; 10 g/100g Gel NDC 59088-488-07
- Urea 41% 410 mg/g Cream NDC 59088-489-16
- Multitam Folic Acid 30 mg; 200 mg; 35 ug; 20 mg; 45 ug; 55 ug; 20 ug; 3.4 mg; 20 mg; 120 mg Tablet NDC 59088-525-54
- DermacinRx Zinc Oxide Skin Healing 200 mg/g Paste NDC 59088-563-01
- DermacinRx Skin Moisturizing Ultra SPF 50 Sunscreen avobenzone, octinoxate, octisalate, titanium dioxide 25 mg/mL; 30 mg/mL; 30 mg/mL; 12.5 mg/mL Lotion NDC 59088-568-05
- PharmapureRx Lidocaine HCl 4.12% Lidocaine Hydrochloride 41.2 mg/g Cream NDC 59088-594-03
- DiaSinc Benzalkonium Chloride 1.3 mg/mL Spray NDC 59088-596-16
- Dimopair Dimethicone 50 mg/mL Cream NDC 59088-623-08
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Dotremin™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Take one tablet daily or as directed by a healthcare practitioner. Dotremin™ should be administered under the supervision of a licensed medical practitioner.
⛔ Contraindications ▾
CONTRAINDICATIONS This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Dotremin ™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.
⚠️ Warnings and Cautions ▾
WARNINGS AND PRECAUTIONS KEEP OUT OF THE REACH OF CHILDREN. Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breastfeeding.
Consult your doctor. Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid. You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY The in vivo synthesis of the major biologically active metabolites of Vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization.
Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules. There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Dotremin™ Tablets are supplied as round, light yellow tablets with one side scored, the other side plain and dispensed in child-resistant bottles of 30 tablets (NDC 59088-524-54*). * This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels (AUG 2, 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B 12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as in some cases, for insurance-reimbursement applications.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision.
There are no implied or explicit claims on therapeutic equivalence
📦 Storage and Handling ▾
STORAGE KEEP OUT OF THE REACH OF CHILDREN. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from heat, light, and moisture. Tamper Evident: Do not use if seal is broken or missing
📋 Description ▾
DESCRIPTION Dotremin™ is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation due to Vitamin D deficiency. Dotremin™ should be administered under the supervision of a licensed medical practitioner. Each tablet contains: Folate (as folic acid)……………………..1700 mcg DFE † (1000 mcg folic acid) Vitamin D 3 (cholecalciferol)………....250 mcg (10,000 IU) Each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, stearic acid, DL-alpha- tocopheryl acetate. † Dietary Folate Equivalent
📄 Package Label / Principal Display Panel ▾
Dotremin™ Manufactured in the USA by: PureTek Corporation Panorama City, CA 91402 For questions or information call toll-free: 877-921-7873 label
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |